A New Scaffold Emerges: Phthalazinone-Imidazoline Hybrids Target Undruggable Kinases
Recent research presents a novel class of dual inhibitors based on a phthalazinone core fused with an imidazoline moiety. This hybrid scaffold demonstrates a unique binding mode, effectively targeting a specific kinase family long considered challenging for small-molecule intervention. Preliminary in vitro assays reveal potent inhibitory activity at nanomolar concentrations against a key oncogenic target, with initial selectivity profiles suggesting…
Continue reading to unlock the full analysis, deeper implications, and why this study may matter for your field.
Unlock Full Briefing — 50% Off with Coupon: ERWMCWYU
Full version includes the complete summary, study significance, and direct link to the original source.
Stay curious. Stay informed — with Science Briefing.
This is a preview briefing. Upgrade to access the full version.
